Influence of CAR-T Product Selection on Survival and Acute Toxicities in Multiple Myeloma: A Real-World Comparative Study

Key Points

• Survival rates vary significantly among multiple myeloma treatments utilizing CAR-T therapies, impacting patient outcomes.
• Acute toxicities, notably severe reactions, were highest in certain CAR-T products, with rates exceeding 30%.
• Observational analysis assessed real-world outcomes for patients undergoing various CAR-T interventions, revealing critical insights.
• These findings highlight the importance of careful CAR-T product selection to optimize treatment and minimize adverse effects.